• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by OmniAb Inc.

    4/29/25 4:12:20 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    DEFA14A 1 a2024proxydefa14awnoticeca.htm DEFA14A 2024 Proxy DEFA 14A w/ Notice Card

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _________________
    SCHEDULE 14A
    SCHEDULE 14A INFORMATION
    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )
    _________________
    Filed by the Registrant x
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material under §240.14a-12
    OmniAb, Inc.
    (Name of Registrant as Specified in Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other Than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required
    Fee paid previously with preliminary materials
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     
    Step 1: Go to www.envisionreports.com/OABI. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/OABI Online Go to www.envisionreports.com/OABI or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 0453WA Important Notice Regarding the Availability of Proxy Materials for the OmniAb, Inc. Shareholder Meeting to be Held on Tuesday June 17, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to shareholders are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 6, 2025 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by 11:59 pm, Pacific Time, on June 16, 2025.


     
    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/OABI. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials OmniAB, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 6, 2025. OmniAb, Inc.’s Annual Meeting of Shareholders will be held on Tuesday June 17, 2025 at 5980 Horton Street, Suite 600, Emeryville, CA 94608, at 8:00 a.m. Pacific Time. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposal 2: 1. Election of Directors: 01 - Carolyn R. Bertozzi, Ph.D. 02 - John Higgins 2. Ratification of Ernst & Young LLP as OmniAb, Inc.’s independent registered accounting firm PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Shareholder Meeting Notice


     
     
    Get the next $OABI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    SEC Filings

    View All

    OmniAb Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - OmniAb, Inc. (0001846253) (Filer)

    1/30/26 4:04:54 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    12/8/25 7:17:46 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    12/8/25 7:15:23 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Higgins John L converted options into 13,172 shares, increasing direct ownership by 0.45% to 2,942,320 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    1/30/26 4:07:25 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Legal Officer Berkman Charles S sold $15,766 worth of shares (8,044 units at $1.96) and converted options into 15,621 shares, increasing direct ownership by 2% to 377,071 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    12/9/25 9:02:55 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Executive VP, Finance and CFO Gustafson Kurt A converted options into 46,500 shares and sold $46,887 worth of shares (23,922 units at $1.96), increasing direct ownership by 10% to 252,688 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    12/9/25 9:02:09 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Platform Technologies Drive $211B Surge in Precision Cancer Treatment

    Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer drug revenues, reflecting investor confidence in technologies that engineer specific biological outcomes[2]. Companies deploying proprietary platforms to target previously undruggable proteins are capturing premium valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc.

    12/11/25 10:17:00 AM ET
    $ERAS
    $FHTX
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Biological Products (No Diagnostic Substances)

    OmniAb to Hold OmniUltra Virtual Investor Event on December 15

    OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What:   OmniUltra Launch Virtual Investo

    12/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Higgins John L bought $107,707 worth of shares (77,261 units at $1.39), increasing direct ownership by 3% to 2,929,148 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    11/10/25 8:30:36 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/15/25 4:02:17 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/14/25 5:04:09 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on OmniAb with a new price target

    RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

    11/29/23 7:31:15 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Benchmark Company initiated coverage on OmniAb with a new price target

    The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

    4/21/23 7:43:22 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Craig Hallum initiated coverage on OmniAb with a new price target

    Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

    4/13/23 9:08:06 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Leadership Updates

    Live Leadership Updates

    View All

    OmniAb Appoints Steve Love to its Board of Directors

    OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

    11/1/23 9:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Financials

    Live finance-specific insights

    View All

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Hold OmniUltra Virtual Investor Event on December 15

    OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What:   OmniUltra Launch Virtual Investo

    12/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. "Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio. Importantly, OmniAb's innovative technology platform and operational model

    11/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

    SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

    11/14/24 4:06:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

    SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

    7/2/24 5:00:16 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care